scholarly journals Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study

2021 ◽  
Author(s):  
Yael Morgenstern ◽  
Shlomzion Aumann ◽  
Neta Goldschmidt ◽  
Moshe E. Gatt ◽  
Boaz Nachmias ◽  
...  
Keyword(s):  
Retrospective Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Newly Diagnosed ◽  
Frontline Treatment

scholarly journals Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

2021 ◽  
Vol 10 (8) ◽  
pp. 1768
Author(s):  
Zhitao Wang ◽  
Rui Jiang ◽  
Qian Li ◽  
Huiping Wang ◽  
Qianshan Tao ◽  
...  
Keyword(s):  
B Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Suppressor Cells ◽  
B Cell Lymphoma ◽  
Pathological Process ◽  
Newly Diagnosed ◽  
Large B Cell Lymphoma ◽  
Accumulation Mechanism ◽  
Large B Cell

Myeloid-derived suppressor cells (MDSCs) are defined as negative regulators that suppress the immune response through a variety of mechanisms, which usually cluster in cancer, inflammation, and autoimmune diseases. This study aims to investigate the correlation between M-MDSCs and the clinical features of diffuse large B-cell lymphoma (DLBCL) patients, as well as the possible accumulation mechanism of M-MDSCs. The level of M-MDSCs is significantly increased in newly diagnosed and relapsed DLBCL patients. Regarding newly diagnosed DLBCL patients, the frequency of M-MDSCs is positively correlated with tumor progression and negatively correlated with overall survival (OS). More importantly, the level of M-MDSCs can be defined as a biomarker for a poor prognosis in DLBCL patients. Additionally, interleukin-35 (IL-35) mediates the accumulation of M-MDSCs in DLBCL patients. Anti-IL-35 treatment significantly reduces levels of M-MDSCs in Ly8 tumor-bearing mice. Thus, M-MDSCs are involved in the pathological process of DLBCL. Targeting M-MDSCs may be a promising therapeutic strategy for the treatment of DLBCL patients.

Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: A retrospective study in China

2013 ◽  
Vol 115 (2) ◽  
pp. 137-143 ◽  
Author(s):  
Cheng-Ru Hu ◽  
Jing-Hua Wang ◽  
Rui Wang ◽  
Qian Sun ◽  
Long-Bang Chen
Keyword(s):  
Risk Factors ◽  
Retrospective Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals A Multicenter Retrospective Study of 58 Patients With Primary Thyroid Diffuse Large B Cell Lymphoma

2020 ◽  
Vol 11 ◽  
Author(s):  
Jianing Yi ◽  
Pingyong Yi ◽  
Wei Wang ◽  
Huan Wang ◽  
Xinyu Wang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document